| Description |
1 online resource |
| Series |
Chapman & Hall/CRC biostatistics series |
|
Chapman & Hall/CRC biostatistics series
|
| Contents |
Front Cover; Contents; Editors; Contributors; Prologue; Chapter 1: Pharmaceutical Benefit-Risk Assessment in Early Development; Chapter 2: Key Questions, Issues, and Challenges in Benefit-Risk Assessment in Full Clinical Development; Chapter 3: The Clinical Aspects of Benefit and Risk; Chapter 4: Quantifying Patient Preferences to Inform Benefit-Risk Evaluations; Chapter 5: Benefit-Risk Modeling of Medicinal Products: Methods and Applications; Chapter 6: Benefit-Risk Communication: Learning from Our Past and Creating Our Future |
|
Chapter 7: Policy Considerations and Strategic Issues Regarding Benefit-RiskChapter 8: Systematic Approaches to Benefit-Risk Assessment; Chapter 9: Considerations and Strategies for Benefit-Risk Assessment in the Real-World Setting; Chapter 10: Benefit-Risk Assessment and the Payer Perspective; Epilogue; Glossary; Back Cover |
| Summary |
Many practitioners in the pharmaceutical industry are still largely unfamiliar with benefit-risk assessment, despite its growing prominence in drug development and commercialization. Helping to alleviate this knowledge gap, Benefit-Risk Assessment in Pharmaceutical Research and Development provides a succinct overview of the key considerations relevant to benefit-risk assessment across the pharmaceutical R & D spectrum, from early clinical development to late-stage development to regulatory review to post-launch assessment. The book first presents interpretations |
| Notes |
Print version record |
| Subject |
Pharmaceutical industry -- Risk management
|
|
Drugs -- Research.
|
|
Drug development -- Research
|
|
Drugs -- Research
|
| Form |
Electronic book
|
| Author |
Sashegyi, Andreas, editor
|
|
Felli, James, editor
|
|
Noel, Rebecca, editor
|
| ISBN |
143986795X |
|
9781439867952 |
|
1306086086 |
|
9781306086080 |
|
